NEW YORK (GenomeWeb News) – Global Genomics Group and Metabolon today announced a collaboration aimed at discovering novel biomarkers and drug targets for cardiovascular diseases.

As part of the deal, Metabolon will use its TrueVision metabolomics offering to analyze biochemicals for a study called Genetic Loci and Burden of Atherosclerotic Lesions, or GLOBAL. The study combines genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics, and lipoprotein proteomics with coronary computed tomographic angiography.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.